ScandiBio Therapeutics is a biotechnology company founded by researchers from the KTH Royal Institute of Technology, Karolinska Institutet and Sahlgrenska Academy in Sweden. The science originates from research conducted at the Science for Life Laboratory in Stockholm (reference Dr Adil Mardinoglu and professor Mathias Uhlén) together with researchers at the Sahlgrenska Academy in Göteborg (reference Professor Jan Borén). A platform for AI-based modelling of biology and medicine has been developed to allow potential treatment of diseases with metabolic dysfunction. The company has developed a combined metabolic cofactor supplementation (CMCS) now in clinical trials aimed to improve for patients with various diseases of metabolic origin.
Chairman
Board Member
Board Member